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Background: In breast cancer, diabetes diagnosed prior to cancer (previously diagnosed) is associated with
advanced cancer stage and increased mortality. However, in the general population, 40% of diabetes is
undiagnosed until glucose testing, and evidence suggests one consequence of increased evaluation and
management around breast cancer diagnosis is the increased detection of previously undiagnosed diabetes.
Biological factors – for instance, higher insulin levels due to untreated disease - and others underlying the
association between previously diagnosed diabetes and breast cancer could differ in those whose diabetes
remains undiagnosed until cancer. Our objectives were to identify factors associated with previously undiagnosed
diabetes in breast cancer, and to examine associations between previously undiagnosed diabetes and cancer stage,
treatment patterns, and mortality.
Methods: Using Surveillance, Epidemiology, and End Results-Medicare, we identified women diagnosed with breast
cancer and diabetes between 01/2001 and 12/2005. Diabetes was classified as previously diagnosed if it was
identified within Medicare claims between 24 and 4 months before cancer diagnosis, and previously undiagnosed
if it was identified from 3 months before to ≤ 3 months after cancer. Patients were followed until 12/2007 or death,
whichever came first. Multivariate analyses were performed to examine risk factors for previously undiagnosed
diabetes and associations between undiagnosed (compared to previously diagnosed) diabetes, cancer stage,
treatment, and mortality.
Results: Of 2,418 patients, 634 (26%) had previously undiagnosed diabetes; the remainder had previously
diagnosed diabetes. The mean age was 77.8 years, and 49.4% were diagnosed with in situ or stage I disease.
Age > 80 years (40% of the cohort) and limited health system contact (primary care physician and/or preventive
services) prior to cancer were associated with higher adjusted odds of previously undiagnosed diabetes. Previously
undiagnosed diabetes was associated with higher adjusted odds of advanced stage (III/IV) cancer (Odds Ratio =
1.37: 95% Confidence Interval (CI) 1.05 – 1.80; P = 0.02), and a higher adjusted mortality rate due to causes other
than cancer (Hazard Ratio = 1.29; 95% CI 1.02 – 1.63; P = 0.03).
Conclusions: In breast cancer, previously undiagnosed diabetes is associated with advanced stage cancer and
increased mortality. Identifying biological factors would require further investigation.
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Epidemiologic evidence suggests pre-existing diabetes is
associated with increased risk of breast cancer [1],
advanced cancer stage at diagnosis [2-5], altered treat-
ment regimens [2,6-8], chemotherapy toxicity [6], breast
cancer mortality in the general population [1,9,10], and
overall mortality in those diagnosed with breast cancer
[2-8,11]. Evidence supporting the association between
pre-existing diabetes and overall mortality in breast cancer
is extensive. Recently, Peairs and colleagues [2] conducted
a systematic review and meta-analysis in which they com-
bined results from 6 studies [6-8,12-14], and found dia-
betes was associated with a 49% increased risk of death
due to all causes. Studies on the association between dia-
betes and cancer mortality in those diagnosed with breast
cancer have produced inconsistent findings [2,6,11,15].
One based on the National Cancer Institute’s (NCI)
Surveillance, Epidemiology, and End Results (SEER)
– Medicare database showed diabetes was associated
with a 10% increase in breast cancer deaths [11]; in
another, only those who received adjuvant chemo-
therapy were at significantly increased risk [6]; while
in a third [15] there was no association between
pre-existing diabetes and cancer mortality.
Biological links between diabetes and breast cancer
risk and outcomes include hyperinsulinemia, hypergly-
cemia, and chronic inflammation [16-18]. Hyperinsuline-
mia related to underlying insulin resistance stimulates
tumor growth, working directly on epithelial cells or
indirectly by activating insulin-like growth factor path-
ways or altering endogenous sex hormones [2]. Several
other factors may link diabetes to breast cancer out-
comes: presentation with later-stage cancer due to sub-
optimal breast cancer screening practices [19,20] or
other health-seeking behavior [21-23]; interactions in
the management of the two conditions, including less
aggressive breast cancer treatment due to diabetes-related
comorbidity [6,7]; poorer response to treatment; and,
possibly, that the diagnosis of breast cancer may distract
both the patient and the health care team from the
appropriate management of glycemia [24].
Thus far, most epidemiology studies of diabetes and
breast cancer outcomes have classified patients as having
diabetes if it was diagnosed prior to cancer, including
several studies based on SEER-Medicare [6,11,15] that
identified diabetes from Medicare claims [25,26] during
12 months prior to cancer. However, in the general adult
population, approximately 40% of diabetes remains un-
diagnosed until glucose testing [27], and there is also
evidence many diabetes cases may remain undiagnosed
until breast cancer [28]. Recently, we conducted a study
in SEER-Medicare to examine the impact of breast
cancer diagnosis on the detection of other previously
undiagnosed conditions, including diabetes [28]. Theprevalence of pre-existing diabetes in the cancer patients
was 14.3%, and it was similar in a cohort of matched
controls (12.8%). However, the incidence of undiagnosed
diabetes was 35.0/1,000 compared to only 13.5/1,000
after a matched sham date in the controls, suggesting
that one consequence of increased evaluation and
management around breast cancer diagnosis is the
detection of previously undiagnosed diabetes. Further-
more, Erickson and colleagues [5] found that of breast
cancer patients with hemoglobin A1C (HbA1C) ≥ 7%
(n=91), only 40.7% indicated they had diabetes on a
baseline self-report questionnaire; only 10% of those
with HbA1C of ≥ 6.5% - a current criterion for the
diagnosis of diabetes [29] - self-reported diabetes.
One implication of these findings is that studies on
the outcomes of pre-existing diabetes in breast cancer
may contain in their control groups many patients
with undiagnosed diabetes.
Biological and other links between diabetes and out-
comes in breast cancer may differ between those with
previously undiagnosed compared to previously diag-
nosed diabetes. Hyperinsulinemia could be exacerbated
in those with previously undiagnosed, and presumably
untreated, diabetes, leading to more aggressive tumor
growth. Also, there is evidence that some diabetes treat-
ments influence cancer risk and prognosis. Metformin,
the most commonly used therapy for type II diabetes, is
often prescribed as initial mono- or combination therapy
[17]. Preclinical data show an in vitro effect of metfor-
min in breast cancer cells [2,30], and in an observational
study in humans, metformin was associated with a higher
pathologic complete response among early-stage breast
cancer patients receiving neoadjuvant therapy [31]. In
contrast to the protective effect of metformin, exogenous
insulin use could promote tumor growth resulting in
more advanced stage cancer at diagnosis among those
with previously diagnosed and treated diabetes.
Data directly supporting the hypothesis that breast
cancer outcomes differ between those with pre-existing
and previously undiagnosed diabetes are scarce. Findings
from a study based on the second National Health and
Nutrition Examination Survey (NHANES) do suggest
cancer mortality in patients with previously undiagnosed
diabetes may be higher than in previously diagnosed dia-
betes, where undiagnosed diabetes was detected through
oral glucose tolerance testing [32]. However, this study
was conducted in the general population, the two dia-
betes groups were not compared directly, and breast
cancer was not assessed separately. Data on the inci-
dence and risk factors for previously undiagnosed dia-
betes in cancer also are scarce. In a SEER-Medicare
study, we reported that detection of many chronic con-
ditions, including diabetes, increases around the time of
breast cancer diagnosis [28], but a detailed examination
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previously diagnosed conditions was beyond the scope of
that study.
The objectives of the present study were (A) to identify
demographic, socioeconomic, and clinical factors associated
with previously undiagnosed, compared to previously diag-
nosed, diabetes in a cohort of breast cancer patients, all of
whom had diabetes, and (B) to examine associations
between previously undiagnosed, compared to previously
diagnosed, diabetes and stage at breast cancer diagnosis,
treatment patterns, and mortality.
Methods
Data source
The source of data for this study was SEER-Medicare
[33]. Presently, SEER contains cancer incidence and
survival data from 17 population-based cancer registries
throughout the United States covering approximately
28% of the population [34]. In SEER-Medicare, cancer
registry data are linked to Medicare enrollment and claims
data, which are available for 93% of those aged ≥ 65 years
in the SEER registry [35].
Inclusion and exclusion criteria
Patients were included if they were diagnosed with
breast cancer between January 1, 2001, and December
31, 2005, breast was the first and only type of cancer at
the time they were diagnosed, they met the minimum
age requirement for Medicare eligibility (65 years), they
had at least 24 months of Medicare Part A (hospital)
and Part B (outpatient) fee-for-service coverage prior to
the diagnosis of cancer, and they were diagnosed with
diabetes between 24 months before and 3 months after
cancer diagnosis. We restricted the cohort to those with
Part A and B coverage because the vast majority of in-
patient and outpatient services for these patients are
captured within the SEER-Medicare database. Patients
were excluded for the following reasons: male breast
cancer; cancer diagnosis made by death certificate or
autopsy; death within the first month following diagno-
sis; or qualification for Medicare based on disability
alone. Requiring all patients to be at least 65 years old at
diagnosis and to have at least 24 months of Medicare
coverage prior to cancer diagnosis meant that the mini-
mum age at cancer diagnosis in the study was 67 years.
Observation period
Patients were followed from 24 months before cancer
until the end of the claims period (December 31, 2007)
or death or the occurrence of a second primary cancer,
whichever came first. Since SEER reports only the
month of diagnosis, the first day of that month was
assigned as the date of diagnosis.Diabetes
Diabetes was defined as the presence of one or more of
the following International Classification of Diseases, 9th
Revision, Clinical Modification, (ICD-9-CM) diagnosis
codes in any position in any Medicare claim: 250.xx for
diabetes and complications; 357.2x for polyneuropathy
in diabetes; 362.0x for diabetic retinopathy; and 366.41
for diabetic cataract [25]. This validated algorithm has
been used in other studies of pre-existing diabetes in
breast cancer [6], and has a sensitivity of 74.4% and spe-
cificity of 97.5% using a 2-year look-back period [25].
Laboratory claims were excluded to reduce the likeli-
hood of misclassifying as diabetes cases those patients
only undergoing diagnostic evaluation for suspected
diabetes. We did not include diabetes medications in the
definition since Medicare did not begin covering oral
medications without an intravenous equivalent until
January, 2006.
Patients were classified as having previously diagnosed
diabetes if the first diabetes claim qualifying them for in-
clusion in the study was between 24 and 4 months
(inclusive) prior to cancer diagnosis. They were classified
as having previously undiagnosed diabetes if their first
diabetes claim was between three months before and
three months (inclusive) after cancer diagnosis, or the
beginning of radiation or chemotherapy, or death,
whichever came first.
Patient characteristics
Patients were described according to their demographic,
clinical, and socioeconomic characteristics. Stage at can-
cer diagnosis was based on the SEER-Modified American
Joint Committee on Cancer (AJCC) stage variable [36].
Medicare claims were used to calculate an NCI Comor-
bidity Index score for each patient [26,37-42]. The two
conditions pertaining to diabetes were removed from the
NCI Comorbidity Index to reduce correlation with previ-
ously diagnosed diabetes. Medicare claims also were used
to identify several indicators of poor performance status
[43], a claims-based surrogate for Eastern Cooperative
Oncology Group Performance Status, including the use of
oxygen and related respiratory therapy supplies, wheel-
chair and supplies, home health agency use, and skilled
nursing facility use.
Poor prior health system contact is associated with
advanced cancer stage at diagnosis [21-23], an important
prognostic factor for cancer outcomes. To account for
this in our analyses, we constructed two measures of prior
health system contact 24 to 4 months before cancer based
on this literature [21,22]. First, we constructed a physician
contact index that classified patients according to the
types of ambulatory care visits they received [21]. We
searched the Medicare physician/supplier claims file for
physician outpatient visits, and classified each visit as
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practitioner, general internist, geriatrician, obstetrician/
gynecologist), medical specialist, or other specialist. Other
specialists included general surgeons, ophthalmologists,
orthopedic surgeons, and other surgical specialists [21].
The presence of one or more claims for each type of
physician visit was coded as “1” for that type. Since
only one of the two Medicare outpatient services files
(physician/supplier and “outpatient”) contains information
on physician specialty, the absence of a primary care or
specialist visit in the physician/supplier file should
not be interpreted as absence of any outpatient health
system contact.
Second, we constructed an index of preventive services
based on one developed by Gornick et al. [22], which
includes mammography, screening for colorectal cancer,
Papanicolaou test, screening for glaucoma, influenza
immunization, and pneumonia immunization. The
presence of one or more claims for each type of service
was coded as “1” for that service, and individual scores
were combined in an index consisting of 0, 1, or ≥ 2.
Socioeconomic information at the patient level is not
available through SEER-Medicare. Instead, the dataset
contains information from the 2000 Census, reported at
the tract level in which the patient lives.
Outcomes variables
We examined risk factors for previously undiagnosed
compared to previously diagnosed diabetes, and assessed
associations between previously undiagnosed diabetes
and advanced stage (III or IV) compared to earlier stage
(in situ, I, or II) cancer at diagnosis, time to initial
chemotherapy or radiation, and mortality. We searched
Medicare claims from the date of cancer diagnosis
through the end of the observation period to identify
ICD-9-CM and Healthcare Common Procedure Coding
System codes indicating treatment with chemotherapy
or radiation [44,45]. The date of the first such claim
was used to indicate the beginning of that treatment.
The date of death was assigned using the Medicare
date, if available, even in cases where the SEER date also
was available. The Medicare date was preferred because
it was more current than the SEER date [46]. Where the
Medicare date was missing but the SEER date was avail-
able, the SEER date was used. All other patients were
assumed to be alive at the end of the observation period
(December 31, 2007) based on the fact that they were
required to have Medicare Part A and Part B coverage
for the entire claims period. The cause of death was
classified as cancer or other-cause, using the "CODKM"
variable in the SEER Patient Entitlement and Diagnosis
Summary File through 2007. Cancer mortality included
all deaths due to cancer (CODKM = 001-130), and not
just due to breast cancer (CODKM = 046). Other-causemortality included all other identified causes of death;
e.g., CODKM = 154 “Diseases of Heart”, CODKM = 148
“Diabetes Mellitus”. However, it excluded missing or un-
specified cause of death. These patients were censored at
the time of death in both the cancer and non-cancer mor-
tality analysis, but considered “events” in the analysis of
all-cause mortality. Cancer and other-cause mortality were
examined separately since the incremental impact of pre-
viously undiagnosed diabetes could differ between
these two.
Analyses
We described the demographic, socioeconomic, and
clinical characteristics of the cohort, both overall and
stratified by previously diagnosed versus previously un-
diagnosed diabetes. Multivariate analysis was used to
evaluate a priori hypotheses about factors associated
with previously undiagnosed diabetes, and the relation-
ships between previously undiagnosed diabetes and out-
comes as specified in a causal pathway diagram
(Figure 1) [47]. Figure 1 shows that we hypothesized a
directed path (A) from a vector of demographic, socioe-
conomic, and clinical characteristics to previously un-
diagnosed diabetes. However, since there are also
directed paths from both previously undiagnosed dia-
betes and the vector of demographic, socioeconomic,
and clinical characteristics to cancer stage at diagnosis,
cancer stage is a collider variable [47-49]. Conditioning
on a collider can open a biasing pathway between two
variables, in this case between the vector of patient
characteristics and previously undiagnosed diabetes,
making it appear that there is an association when in
fact none exists. Therefore, in the multivariate
analyses of factors associated with previously undiag-
nosed diabetes, we excluded cancer stage from the
vector of independent variables in the models.
Figure 1 shows that there is a directed path and an un-
directed path (through demographic, socioeconomic,
and clinical characteristics) from previously undiagnosed
diabetes to cancer stage (in situ/I/II versus III/IV) at
diagnosis. Therefore, adding confounders to a logistic re-
gression model of previously undiagnosed diabetes and
advanced stage cancer should attenuate (by blocking the
undirected path) but not completely eliminate – the
directed path should remain open – the association
between previously undiagnosed diabetes and advanced
stage. Since there is strong evidence linking higher levels
of prior health system contact to early stage cancer diag-
nosis, we reasoned that these covariates could be strong
confounders in the association between previously
undiagnosed diabetes and cancer stage. Therefore, we
estimated two logistic regression analyses to evaluate the
effect of adding the measures of prior health system con-













B Is there an association between 
previously undiagnosed diabetes and 
cancer stage at diagnosis, controlling for 
other factors?  
A  What factors are associated 
with previously undiagnosed 
compared to previously 
diagnosed diabetes?
A
C  Is there an association between 
previously undiagnosed diabetes and 
mortality, controlling for other factors?  
Figure 1 Causal pathway diagram. Prior to finalizing the inclusion/exclusion criteria and hypotheses for this study, a causal diagram was
developed to visually encode a priori assumptions about the relation between exposure (previously undiagnosed versus previously diagnosed
diabetes), outcomes, and covariates, taking into account the strengths and limitations of the Surveillance, Epidemiology, and End Results (SEER) -
Medicare database. The diagram depicts directed paths (a head-to-tail sequence of arrows, or a “one-way street”) between previously undiagnosed
diabetes and both cancer stage at diagnosis and mortality. One of the directed paths between previously undiagnosed diabetes and mortality
contains cancer stage as an intermediate variable. In other words, the impact of previously undiagnosed diabetes on mortality is partially
explained by its intermediate impact on cancer stage. The other directed path contains no intermediate variables. In addition, the diagram
depicts undirected paths (paths in which the arrows are not all head-to-tail) between previously undiagnosed diabetes and both cancer stage at
diagnosis and mortality, which “flow through” patient demographic, socioeconomic, and clinical characteristics. In this instance, the undirected
paths between previously undiagnosed diabetes, cancer stage, and mortality are biasing paths (and the variables on those paths are potential
confounders) for the association between exposure and outcomes because they do not represent effects of previously undiagnosed diabetes on the
outcomes, yet can contribute to (confound) the association between previously undiagnosed diabetes and outcomes. These should be “blocked” either
by study design, including patient selection, or by adjustment in the analyses, to maximize the likelihood that the observed residual associations
between exposure and outcomes are unbiased.
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race/ethnicity, year of cancer diagnosis, NCI Comorbidity
Index, performance status, education, poverty, and
geographic area as covariates.
Figure 1 also shows that there are two directed paths
and two undirected paths between previously undiag-
nosed diabetes and mortality. In addition, one of the
directed paths includes cancer stage at diagnosis as an
intermediate variable. Therefore, the causal diagram
suggests that adding measures of prior health system
contact to a model that includes other covariates should
attenuate, but not eliminate, the observed (and biased)
association between previously undiagnosed diabetes
and mortality. In addition, adding cancer stage as a
covariate should block the directed path in which
cancer stage is an intermediate variable, further
attenuating the observed association between previously
undiagnosed diabetes and mortality. However, it is
important to note that blocking this directed path can
be construed as over-adjustment, since the directed
path is not a biasing path.
To explore these associations, we ran four sets of three
multivariate survival analyses. Each set included all-
cause, cancer, and other-cause mortality as independentvariables, and age, race/ethnicity, year of cancer diagno-
sis, NCI Comorbidity Index, performance status, estro-
gen and progesterone receptor (ER PR) status, histology,
education, poverty, and geographic area as covariates.
We then added both measures of prior health system
contact and cancer stage, separately and together, to the
base set of covariates in order to examine their impact
on the coefficient for previously undiagnosed diabetes.
The base-case model included both measures of prior
health system contact, but not cancer stage. During the
exploratory phase of our study, we did sequential ana-
lyses in which we introduced first one and then the
second measure of prior health system contact into our
models. We found that while the effect of the first intro-
duced was attenuated by the second, in almost all
instances both remained statistically and clinically
significant. Therefore, both were retained in the models
that included prior health system contact.
Results
The final cohort included 2,418 breast cancer patients
with diabetes, of whom 1,784 (73.8%) had previously
diagnosed and the remaining 634 (26.2%) had previously
undiagnosed diabetes. Overall, the mean age was 77.8
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with in situ or stage I disease, and 49.3% were both ER
and PR positive (Table 1).
The multivariate analysis of factors associated with
previously undiagnosed (compared to previously diag-
nosed) diabetes (Table 2) showed that later year of
cancer diagnosis, higher NCI Comorbidity Index, ≥ 1
indicator of poor performance, at least one visit to a
primary care physician or medical specialist, receiv-
ing ≥ 2 preventive services, and living in a less urban/
rural area all were associated with significantly lower
odds of previously undiagnosed diabetes. The results
also suggest age > 80 years was associated with higher
odds of previously undiagnosed diabetes; however,
the odds ratio (OR) for this covariate narrowly failed
to reach the commonly accepted threshold for statistical
significance (P < 0.05).
Cancer stage at diagnosis
Overall, 18.1% of all patients (n=438) were diagnosed
with stage III/IV breast cancer: 15.9% (n=283) of those
with previously diagnosed diabetes, and 24.4% (n=155)
with previously undiagnosed diabetes (p < 0.0001 for un-
adjusted difference in distribution across all 5 cancer
stages [Bivariate results shown in Table 1]). In a multi-
variate analysis (reported in the text below) that
excluded measures of prior health system contact, the
odds of being diagnosed with stage III/IV disease
were 76% higher (OR=1.76; 95% Confidence Interval
[CI] 1.37 – 2.28; p < 0.0001) for patients with previ-
ously undiagnosed diabetes (compared to previously
diagnosed diabetes). When measures of prior health
system contact were introduced, the OR for previ-
ously undiagnosed diabetes decreased to 1.37, but
remained statistically significant (95% CI 1.05 – 1.80;
p = 0.02). Both measures of prior health system con-
tact (types of physician contact and preventive
services) were statistically significant in the latter
model, showing less/poor quality prior health system
contact was associated with significantly increased
odds of advanced stage at diagnosis. Those living in a
census tract with > 12% poverty were more likely to
be diagnosed with advanced stage disease, although
this effect was attenuated slightly by the introduction
of the aforementioned measures of prior health
system contact.
Initial treatment
Overall, 479/2,418 (19.8%) received chemotherapy:
18.6% of those with previously diagnosed diabetes and
23.3% of those with previously undiagnosed diabetes. In
addition, 662/2,418 (27.4%) received radiation: 28.1% of
those with previously diagnosed diabetes and 25.2% of
those with previously undiagnosed diabetes. In multivariateanalysis of time to initial treatment, there was no difference
in time to initial chemotherapy (Hazard Ratio [HR] = 1.08;
95% CI 0.87 – 1.34; P = 0.50), radiation (HR = 0.86; 95%
CI 0.71 – 1.04; P = 0.12), or either chemotherapy or radi-
ation, whichever came first (HR = 0.89; 95% CI 0.76 –
1.04; P = 0.14), between those with previously undiag-
nosed and those with previously diagnosed diabetes,
adjusting for all patient factors reported in Table 1.
Age > 80 years at diagnosis, in situ or stage I disease,
and being both ER and ER positive were associated
with lower rates of chemotherapy and radiation. In
contrast, stage III or IV (compared to stage II, the
reference category) disease was associated with higher
rates (HRs not shown).
Mortality
Overall, 980/2,418 (40.5%) died during the observation
period: 40.2% of those with previously diagnosed dia-
betes and 41.5% of those with previously undiagnosed
diabetes. The estimated median survival based on
Kaplan-Meier analysis was 68.6 months in those with
previously diagnosed diabetes and 62.3 months in those
with previously undiagnosed diabetes. In multivariate
survival analysis that included all covariates in Table 1
except cancer stage and the two measures of prior health
system contact (types of physician contact and prevent-
ive services), previously undiagnosed (compared to pre-
viously diagnosed) diabetes was associated with
significantly higher all-cause (HR = 1.25; 95% CI 1.08 –
1.45; P < .01), cancer (HR = 1.33; 95% CI 1.04 –
1.70; P = 0.03), and other-cause mortality (HR = 1.39;
95% CI 1.11 – 1.75; P = 0.01). Adding measures of
prior health system contact to the (base-case) model
reduced the magnitude and statistical significance of
the HR for previously undiagnosed diabetes on all
three measures of mortality: all-cause (HR = 1.13;
95% CI 0.97 – 1.32; P = 0.11), cancer (HR = 1.08;
95% CI 0.84 – 1.40; P = 0.54), and other-cause mor-
tality (HR = 1.29; 95% CI 1.02 – 1.63; P = 0.03).
(Table 3) Adding cancer stage further attenuated the
associations between previously undiagnosed diabetes
and mortality. However, as discussed in the Methods,
these models may be over-adjusted since cancer stage was
hypothesized to be an intermediate variable between pre-
viously undiagnosed diabetes and mortality (Figure 2).
In the base-case survival analyses, (Table 3) other
factors associated with a significantly higher cancer mor-
tality rate were age > 80 years at cancer diagnosis, ER-
and PR-negative disease, and higher grade histology.
Primary care physician and/or medical specialist contact
prior to cancer diagnosis, receipt of ≥ 2 preventive ser-
vices, and ER- and PR-positive disease were associated
with a significantly lower cancer mortality rate. Factors
associated with significantly higher other-cause mortality
Table 1 Patient characteristics
Diabetes status at cancer diagnosis
Overall (N = 2,418) Previously diagnosed (n = 1,784) Previously undiagnosed (n = 634) P-value
N % (SD) n % (SD) n % (SD)
Age at cancer diagnosis (years)
66-70 326 13.5% 234 13.1% 92 14.5% 0.77
71-75 529 21.9% 397 22.3% 132 20.8%
76-80 594 24.6% 437 24.5% 157 24.8%
>80 969 40.1% 716 40.1% 253 39.9%
Mean & (SD) age 77.8 6.9 77.8 7.0 77.7 6.9
Race/ethnicity
White 2,156 89.2% 1,584 88.8% 572 90.2% 0.47
Black 132 5.5% 103 5.8% 29 4.6%
Hispanic 89 3.7% 64 3.6% 25 3.9%
Other 41 1.7% 33 1.8% 8 1.3%
Year of diagnosis
2001 464 19.2% 322 18.0% 142 22.4% 0.05
2002 482 19.9% 347 19.5% 135 21.3%
2003 466 19.3% 347 19.5% 119 18.8%
2004 468 19.4% 363 20.3% 105 16.6%
2005 538 22.2% 405 22.7% 133 21.0%
Stage at diagnosis
In situ 274 11.3% 217 12.2% 57 9.0% <0.0001
I 920 38.0% 705 39.5% 215 33.9%
II 786 32.5% 579 32.5% 207 32.6%
III 239 9.9% 175 9.8% 64 10.1%
IV 199 8.2% 108 6.1% 91 14.4%
Estrogen (ER) and progesterone (PR) receptor status
ER and PR positive 1,193 49.3% 881 49.4% 312 49.2%
ER or PR positive 327 13.5% 238 13.3% 89 14.0% 0.89
ER and PR negative 324 13.4% 244 13.7% 80 12.6%
Unknown/missing 574 23.7% 421 23.6% 153 24.1%
Histologic grade
1 447 18.5% 336 18.8% 111 17.5% 0.61
2 872 36.1% 652 36.5% 220 34.7%
3 696 28.8% 502 28.1% 194 30.6%
4 71 2.9% 49 2.7% 22 3.5%
Unknown/missing 332 13.7% 245 13.7% 87 13.7%
NCI Comorbidity Index
0 1,051 43.5% 627 35.1% 410 64.7% <0.0001
1 699 28.9% 560 31.4% 145 22.9%
≥ 2 668 27.6% 597 33.5% 79 12.5%
Indicators of poor performance
0 1,169 48.3% 692 38.8% 477 75.2% <0.0001
≥ 1 1,249 51.7% 1,092 61.2% 157 24.8%
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Table 1 Patient characteristics (Continued)
Types of physician visits
Primary care and medical specialist 1,621 67.0% 1,277 71.6% 344 54.3% <0.0001
Primary care, no medical specialist 381 15.8% 254 14.2% 127 20.0%
Medical specialist, no primary care 226 9.3% 154 8.6% 72 11.4%
Other specialist only 57 2.4% 34 1.9% 23 3.6%
None 133 5.5% 65 3.6% 68 10.7%
Preventive services
0 236 9.8% 123 6.9% 113 17.8% <0.0001
1 403 16.7% 294 16.5% 109 17.2%
≥ 2 1,779 73.6% 1,367 76.6% 412 65.0%
Percent in census tract with some college
<25% 883 36.5% 656 36.8% 227 35.8% 0.66
≥25% 1,535 63.5% 1,128 63.2% 407 64.2%
Percent in census tract living in poverty
<5% 686 28.4% 509 28.5% 177 27.9% 0.29
5-7% 343 14.2% 255 14.3% 88 13.9%
8-12% 542 22.4% 383 21.5% 159 25.1%
>12% 847 35.0% 637 35.7% 210 33.1%
Type of geographic area
Large metropolitan 1,298 53.7% 952 53.4% 346 54.6% 0.74
Metropolitan 696 28.8% 510 28.6% 186 29.3%
Urban 165 6.8% 125 7.0% 40 6.3%
Less urban/rural 259 10.7% 197 11.0% 62 9.8%
SD: Standard deviation. The NCI Comorbidity Index is based on claims 24 – 4 months before cancer, and excludes two diabetes-related conditions.
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http://www.biomedcentral.com/1471-2407/12/613were age > 80 years, NCI Comorbidity Index score of 1
or ≥ 2, at least one indicator of poor performance, and
living in a census tract with ≥ 25% college educated.
Primary care physician contact prior to cancer diagnosis
was associated with significantly lower other-cause
mortality.
Discussion
Pre-existing diabetes is associated with increased risk of
breast cancer [1] and adverse outcomes [2]. Biological
and other factors underlying the association between
pre-existing diabetes and breast cancer could differ in
those whose diabetes remains undiagnosed until cancer.
In this study, we identified a cohort of women diagnosed
with both breast cancer and diabetes. We divided the
cohort into two groups: those with previously diagnosed
diabetes and those with previously undiagnosed diabetes.
We then described risk factors and outcomes associated
with previously undiagnosed compared to previously
diagnosed diabetes.
More than one quarter of the patients had previously
undiagnosed diabetes, which is somewhat lower than
rates of previously undiagnosed diabetes based onglucose testing in the general population [27] or in those
with breast cancer [5]. Ours may be a conservative esti-
mate since we used medical claims from a six-month
period around the diagnosis of breast cancer to identify
previously undiagnosed diabetes, and the algorithm we
used has a reported sensitivity of approximately 74%
[25]. Among the risk factors for previously undiag-
nosed diabetes was low level of health system contact
prior to cancer. Specifically, those with lower
utilization of preventive services and less contact with
primary care physicians or medical specialists were at
significantly higher risk of previously undiagnosed
diabetes. We did not include cancer stage as a covari-
ate in the multivariate analyses of factors associated
with previously undiagnosed diabetes, because our
causal pathway diagram indicates it is a collider [47-49]
in this instance. Consequently, conditioning on stage
could have opened a biasing pathway (the analysis
may have identified an association where none exists)
between the vector of patient characteristics and
previously undiagnosed diabetes.
Our findings show that previously undiagnosed diabetes
is associated with higher odds of being diagnosed with
Table 2 Multivariate analysis of factors associated with previously undiagnosed diabetes compared to previously
diagnosed diabetes
Measures of prior health system
contact not included
Measures of prior health system
contact included
OR 95% CI P-Value OR 95% CI P-Value
Lower Upper Lower Upper
Age at cancer diagnosis (years)
66-70 Reference
71-75 0.89 0.63 1.24 0.49 0.95 0.67 1.34 0.75
76-80 1.12 0.80 1.55 0.52 1.21 0.86 1.70 0.28
>80 1.35 0.99 1.84 0.06 1.35 0.98 1.86 0.07
Race/ethnicity
White Reference
Black 0.89 0.55 1.43 0.62 0.75 0.46 1.24 0.26
Hispanic 1.05 0.62 1.78 0.87 1.02 0.59 1.75 0.95
Other 0.72 0.31 1.67 0.44 0.64 0.27 1.56 0.33
Year of diagnosis
2001 Reference
2002 0.76 0.56 1.03 0.08 0.75 0.55 1.03 0.07
2003 0.69 0.51 0.95 0.02 0.71 0.52 0.98 0.03
2004 0.61 0.44 0.84 <0.01 0.61 0.44 0.85 <0.01
2005 0.69 0.51 0.94 0.02 0.71 0.52 0.97 0.03
NCI Comorbidity Index
0 Reference
1 0.44 0.35 0.56 <0.0001 0.48 0.38 0.61 <0.0001
≥ 2 0.29 0.22 0.40 <0.0001 0.32 0.24 0.44 <0.0001
Indicators of poor performance
0 Reference
≥ 1 0.27 0.22 0.34 <0.0001 0.27 0.21 0.33 <0.0001
Types of physician visits
None Not Applicable Reference
Primary care and medical specialist 0.33 0.21 0.51 <0.0001
Primary care, no medical specialist 0.52 0.32 0.83 0.01
Medical specialist, no primary care 0.50 0.30 0.85 0.01
Other specialist only 0.67 0.32 1.37 0.27
Preventive services
0 Not Applicable Reference
1 0.70 0.47 1.04 0.07
≥ 2 0.58 0.41 0.82 <0.01
Percent in census tract with some college
<25% Reference
≥25% 0.97 0.79 1.20 0.79 0.95 0.76 1.18 0.62
Percent in census tract living in poverty
<5% Reference
5-7% 0.99 0.72 1.37 0.96 0.98 0.70 1.36 0.88
8-12% 1.24 0.94 1.64 0.13 1.21 0.91 1.62 0.18
>12% 1.17 0.88 1.55 0.27 1.04 0.78 1.39 0.78
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Table 2 Multivariate analysis of factors associated with previously undiagnosed diabetes compared to previously
diagnosed diabetes (Continued)
Type of geographic area
Large metropolitan Reference
Metropolitan 0.82 0.65 1.04 0.10 0.85 0.67 1.08 0.18
Urban 0.74 0.49 1.12 0.16 0.78 0.50 1.20 0.25
Less urban/rural 0.72 0.50 1.03 0.07 0.69 0.48 1.00 0.05
OR: Odds ratio. CI: Confidence interval. Not Applicable: Covariates not included in that model.
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http://www.biomedcentral.com/1471-2407/12/613advanced stage breast cancer. Possible explanations
include exacerbated biological mechanisms related to
hyperglycemia, hyperinsulinemia, and inflammation in un-
diagnosed diabetes, which can result in tumor cell prolifera-
tion and metastases [16-18]. However, since we did not
have information on insulin and glucose levels, or on
duration of previously undiagnosed diabetes, these findings
should be considered as hypothesis-generating, requiring
laboratory data and information on unobserved confoun-
ders for further evaluation. Also, although in the causal dia-
gram previously undiagnosed diabetes precedes advanced-
stage cancer diagnosis, since previously undiagnosed
diabetes status was ascertained at the same time as cancer
stage, we cannot conclude that previously undiagnosed
diabetes caused advanced stage cancer in our study.
The potential for confounding in this analysis due
to shared risk factors was significant, as illustrated in
the causal pathway diagram we developed. Since pre-
vious research shows that limited health system con-
tact is associated with advanced stage cancer at
diagnosis [21-23], and limited health system contact
was associated with previously undiagnosed diabetes
in this study, we sought to block this “biasing path-
way” [47] by including measures of prior health
system contact in the final multivariate model of
stage, and in doing so confirmed the earlier findings
[21-23]. Also, we sought to minimize other sources of
potential confounding – due to unobserved factors
that place individuals at higher risk of diabetes – by
limiting the cohort to those with diabetes. Unmeasured
potential confounders include diabetes severity measures,
body-mass index, diabetes treatment/medications, and
other health behavior.
Finally, previously undiagnosed diabetes was asso-
ciated with significantly increased mortality, but this
effect was limited to death from causes other than
cancer. This suggests patients with undiagnosed diabetes
are sicker overall, and are more likely to die from “com-
peting risks” rather than directly from breast cancer.
Any effect of previously undiagnosed diabetes on
cancer mortality appears to be mediated entirely by
advanced stage as an intermediate risk factor, and
poor prior health system contact as a confoundingfactor. It is unclear whether these findings specific to
breast cancer can be generalized to other types of
cancers, where the impact of diabetes on cancer treat-
ment and outcomes may differ. As with the analyses
of previously undiagnosed diabetes and stage, there
are unmeasured potential confounders in the survival
analyses, including cancer treatment, surveillance, and
diabetes-related complications.
Our study has several limitations. As discussed above,
the claims-based algorithm we used to identify diabetes
has a validated sensitivity of 74.4% and specificity of
97.5% using a 2-year look-back period [25]. Therefore,
we have likely missed cases of diabetes that would, for
instance, have been identified through electronic medical
records containing detailed laboratory and oral medica-
tions data. Also, we have described diabetes first
detected three months before to three months after
cancer as previously undiagnosed diabetes, which im-
plies that it was present but undetected prior to that.
However, simply by chance, it is likely that some
patients had new onset diabetes during this period.
Further, it is possible that some of the diabetes cases
we identified as previously undiagnosed would have
been reclassified as previously diagnosed had we
extended the look-back period of the algorithm from
24 to 36 months. However, this would have resulted
in excluding all patients aged 67, who would not have
had at least 36 months of Medicare eligibility prior to
the diagnosis of cancer.
This study was conducted prior to the implementation
of the Medicare Modernization Act (MMA), which
introduced new coverage for diabetes and other screen-
ing services in 2005 [50]. Introduction of these services
is designed to improve early detection of diabetes and
other important conditions. Therefore, rates of previ-
ously undiagnosed diabetes could change as a result of
MMA. In addition to affecting the incidence of previ-
ously undiagnosed diabetes, MMA could impact the
services included in the preventive services measure of
prior health system contact. Since some of the new
services directly impact diabetes, it is possible that asso-
ciations between level of preventive services use and
previously undiagnosed diabetes would become stronger
Table 3 Multivariate survival analysis
All-cause mortality Cancer mortality Other-cause mortality
HR 95% CI P-Value HR 95% CI P-Value HR 95% CI P-Value
Lower Upper Lower Upper Lower Upper
Diabetes status
Previously diagnosed Reference
Previously undiagnosed 1.13 0.97 1.32 0.11 1.08 0.84 1.40 0.54 1.29 1.02 1.63 0.03
Age at cancer diagnosis (years)
66-70 Reference
71-75 1.12 0.88 1.44 0.35 1.31 0.89 1.92 0.18 0.87 0.57 1.31 0.50
76-80 1.47 1.16 1.85 <0.01 1.37 0.93 2.02 0.11 1.40 0.96 2.02 0.08
>80 1.90 1.53 2.36 <0.0001 1.46 1.02 2.09 0.04 2.16 1.54 3.03 <0.0001
Race/ethnicity
White Reference
Black 1.08 0.83 1.40 0.58 1.07 0.69 1.66 0.75 0.95 0.61 1.47 0.82
Hispanic 0.86 0.61 1.21 0.37 1.02 0.61 1.72 0.93 1.15 0.69 1.89 0.60
Other 0.92 0.56 1.51 0.74 0.77 0.28 2.08 0.60 1.07 0.53 2.17 0.86
Year of diagnosis
2001 Reference
2002 1.06 0.89 1.27 0.50 1.23 0.89 1.70 0.22 1.20 0.91 1.57 0.19
2003 1.07 0.89 1.29 0.50 1.05 0.75 1.47 0.79 1.09 0.81 1.45 0.58
2004 0.90 0.73 1.10 0.29 1.05 0.73 1.50 0.80 0.90 0.66 1.24 0.53
2005 1.02 0.83 1.25 0.86 1.15 0.81 1.63 0.44 0.95 0.68 1.33 0.75
Estrogen (ER) and progesterone (PR) receptor status
ER or PR positive Reference
ER and PR positive 0.84 0.70 1.01 0.07 0.64 0.47 0.88 0.01 0.98 0.73 1.31 0.89
ER and PR negative 1.31 1.04 1.64 0.02 1.56 1.10 2.21 0.01 0.90 0.61 1.34 0.61
Unknown/missing 0.86 0.70 1.05 0.14 0.58 0.40 0.83 <0.01 1.06 0.77 1.45 0.74
Histologic grade
1 Reference
2 1.14 0.94 1.39 0.18 2.24 1.42 3.53 <0.01 0.86 0.66 1.12 0.27
3 1.54 1.26 1.88 <0.0001 3.17 2.01 5.01 <0.0001 1.20 0.90 1.59 0.21
4 1.15 0.76 1.72 0.51 3.32 1.65 6.68 <0.01 0.75 0.39 1.46 0.40
Unknown/missing 1.66 1.32 2.08 <0.0001 4.04 2.48 6.57 <0.0001 0.91 0.64 1.28 0.58
NCI Comorbidity Index
0 Reference
1 1.37 1.17 1.61 <0.01 0.99 0.76 1.30 0.96 1.64 1.27 2.12 <0.01
≥ 2 1.83 1.55 2.16 <0.0001 1.11 0.82 1.49 0.51 2.53 1.95 3.27 <0.0001
Indicators of poor performance
0 Reference
≥ 1 1.27 1.10 1.46 <0.01 1.00 0.78 1.28 0.97 1.66 1.33 2.08 <0.0001
Types of physician visits
None Reference
Primary care and medical specialist 0.56 0.44 0.72 <0.0001 0.44 0.30 0.65 <0.0001 0.61 0.40 0.93 0.02
Primary care, no medical specialist 0.70 0.54 0.92 0.01 0.65 0.43 0.98 0.04 0.63 0.39 1.00 0.05
Medical specialist, no primary care 0.72 0.54 0.96 0.02 0.43 0.26 0.70 <0.01 1.11 0.70 1.75 0.66
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Table 3 Multivariate survival analysis (Continued)
Other specialist only 1.02 0.69 1.50 0.94 0.76 0.39 1.46 0.40 1.04 0.55 1.97 0.91
Preventive services
0 Reference
1 0.78 0.63 0.96 0.02 0.78 0.55 1.10 0.15 0.99 0.69 1.42 0.95
≥ 2 0.53 0.43 0.64 <0.0001 0.41 0.29 0.57 <0.0001 0.73 0.52 1.02 0.07
Percent in census tract with some college
<25% Reference
≥25% 1.09 0.96 1.24 0.20 1.16 0.92 1.46 0.21 1.24 1.01 1.52 0.04
Percent in census tract living in poverty
<5% Reference
5-7% 0.97 0.80 1.19 0.79 0.94 0.67 1.31 0.72 0.97 0.72 1.30 0.82
8-12% 0.94 0.79 1.12 0.48 0.80 0.59 1.10 0.17 0.92 0.71 1.20 0.55
>12% 1.07 0.90 1.27 0.45 0.93 0.69 1.25 0.61 0.93 0.71 1.22 0.62
Type of geographic area
Large metropolitan Reference
Metropolitan 0.99 0.86 1.15 0.90 0.80 0.62 1.03 0.09 0.92 0.73 1.15 0.47
Urban 0.97 0.75 1.25 0.80 0.63 0.38 1.06 0.08 0.77 0.49 1.22 0.26
Less urban/rural 0.84 0.67 1.04 0.11 0.60 0.39 0.90 0.01 1.09 0.79 1.51 0.58
HR: Hazard ratio. CI: Confidence interval.
Figure 2 Multivariate survival analyses: sensitivity analysis of adjusted hazard ratios for previously undiagnosed diabetes. This figure
presents the results of four sets of three multivariate survival analyses, which evaluate the sensitivity of the baseline findings reported in Table 3
(upper right quadrant in Figure) based on the inclusion and exclusion of cancer stage at diagnosis and measures of prior health system contact.
Within each quadrant are the results of 3 separate multivariate analyses, one for each mortality outcome. Triangles represent the adjusted hazard
ratios for previously undiagnosed diabetes (compared to previously diagnosed diabetes). Ticks represent the upper and lower bounds of the 95%
confidence interval corresponding to the hazard ratio. Confidence intervals that do not overlap 1.0 are statistically significant at a threshold of P = 0.05.
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http://www.biomedcentral.com/1471-2407/12/613as a result, but that the overall incidence of previously
undiagnosed diabetes has declined through improved
coverage of preventive services.
We considered propensity score analysis. However,
elucidating our pathway diagram required that we
examine the effects of including/excluding specific
covariables, e.g. stage and measures of prior health
system contact, on the associations between previously
undiagnosed diabetes and outcomes, which would not
have been possible had we summarized these effects in a
single propensity score. Finally, it was not our intent in
this study to compare the outcomes of those with versus
without diabetes. Therefore, we did not include a control
group of patients who did not have diabetes.Conclusions
When compared to previously diagnosed diabetes, previ-
ously undiagnosed diabetes is associated with increased
risk of advanced stage cancer. While previously undiag-
nosed diabetes does not appear to confer additional risk
of cancer mortality, it is associated with increased risk of
death due to other causes. The fact that limited prior
health system contact was a risk factor for previously
undiagnosed diabetes, advanced stage cancer, and mor-
tality (cancer and other cause) underscores the import-
ance of continuing to strengthen Medicare coverage for,
and promote use of, routine primary care physician visits
and preventive services, especially for those with shared
risk factors for both breast cancer and diabetes.
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